0
Cell & Gene Therapy Pipelines
0
Biopharma, Big Pharma, CMOs, and Research/Academic Institutes
0
Key Manufacturing Parameter
0
Key Pipeline Parameters:
Tracker Highlights
left
right
comprehensive information

Competitive Assessment

This tracker provides an in-depth overview of the upcoming competition in the global cell & gene therapy market.

Through this tracker, IMAPAC aims to assist organizations to keep track of their competitors, identify any opportunities for collaboration or investments for the development or manufacturing of cell & gene therapies, and support key strategic decisions making for the business.

Explore More, Request A Demoright

Key Pipeline Parameters

Company overview, current cell & gene therapy products in the pipeline, product’s stage of development, product by therapy type, autologous or allogenic therapies, disease or indication, target for each product candidate, route of administration, and technology employed in product’s development.

Explore More, Request A Demoright

Key Manufacturing Parameter

Facility centers, facility size, facility investment, production capacity, types of products manufactured in the facility, key features of the facility, operation scale, process technology, regulatory approvals & certifications, expansion plans and other vital information

Explore More, Request A Demoright

Key Companies Covered

Eureka Therapeutics, Anterogen, Audentes Therapeutics, Biogen Cell, Biostar Stem Cell Research Institute, Carsgen Therapeutics, Evastem, Orthocell, AnGes, Novartis, Autolous Therapeutics, Organogenesis, Poseida Therapeutics, Alaunos Therapeutics, Fate Therapeutics, Spark Therapeutics, Chiesi Farmaceutici, Bluebird Bio among other companies.

Explore More, Request A Demoright
bag